Daniel Spiegelman

2017

In 2017, Daniel Spiegelman earned a total compensation of $4.6M as Executive Vice President, Chief Financial Officer at BioMarin Pharmaceutical, a 5% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$481,380
Option Awards$1,439,891
Salary$559,231
Stock Awards$2,133,048
Other$28,325
Total$4,641,875

Spiegelman received $2.1M in stock awards, accounting for 46% of the total pay in 2017.

Spiegelman also received $481.4K in non-equity incentive plan, $1.4M in option awards, $559.2K in salary and $28.3K in other compensation.

Rankings

In 2017, Daniel Spiegelman's compensation ranked 2,098th out of 14,666 executives tracked by ExecPay. In other words, Spiegelman earned more than 85.7% of executives.

ClassificationRankingPercentile
All
2,098
out of 14,666
86th
Division
Manufacturing
717
out of 5,772
88th
Major group
Chemicals And Allied Products
194
out of 2,075
91st
Industry group
Drugs
147
out of 1,731
92nd
Industry
Pharmaceutical Preparations
114
out of 1,333
91st
Source: SEC filing on April 23, 2019.

Spiegelman's colleagues

We found four more compensation records of executives who worked with Daniel Spiegelman at BioMarin Pharmaceutical in 2017.

2017

Jean-Jacques Bienaim

BioMarin Pharmaceutical

Chief Executive Officer

2017

Henry Fuchs

BioMarin Pharmaceutical

President, Worldwide R&D

2017

Jeff Ajer

BioMarin Pharmaceutical

Executive Vice President, Chief Commercial Officer

2017

Robert Baffi

BioMarin Pharmaceutical

Executive Vice President, Technical Operations

News

You may also like